Isaxonine

CHEMBL1740513 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
137.2 g/mol
LogP
1.3
Phase
4

This neurotropic compound was investigated for its potential to support nerve regeneration and treat peripheral neuropathy, with some early research suggesting it could promote the survival of damaged neurons. It was not widely adopted in clinical practice.

น้ำหนักโมเลกุล

137.1800 g/mol

LogP

1.30

TPSA

37.80 Ų

Lipinski RO5

ผ่าน

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)Nc1ncccn1

InChI

InChI=1S/C7H11N3/c1-6(2)10-7-8-4-3-5-9-7/h3-6H,1-2H3,(H,8,9,10)

Molecular Formula

C7H11N3

HBD / HBA

1 / 3

พันธะที่หมุนได้

2

อะตอมหนัก

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This neurotropic compound was investigated for its potential to support nerve regeneration and treat peripheral neuropathy, with some early research suggesting it could promote the survival of damaged neurons. It was not widely adopted in clinical practice.

Yes, Isaxonine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1740513. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71169. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.